Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk …
2 days ago · News provided by Variant Bio, Inc. Jan 07, 2025, 07:03 ET . Share this article ... Novo Nordisk will pay Variant Bio an upfront payment and additional near-term R&D funding totaling up to $50 ...
Variant, Novo to identify metabolic disease treatment targets
2 days ago · Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment. Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m. January 7, 2025. ... Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology. ...
Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk …
2 days ago · Under the terms of the agreement, Novo Nordisk will pay Variant Bio an upfront payment and additional near-term R&D funding totaling up to $50 million, ... Follow Variant Bio’s news and updates at variantbio.com and via its blog, on X/Twitter @VariantBio, on Instagram @variant_bio, ...
Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk …
1 day ago · The strategic partnership with Novo Nordisk demonstrates the value of Variant Bio’s potential to enable the development of novel therapeutics based on results from its innovative genomic studies. About Variant Bio Variant Bio is developing life-saving therapies by studying the genes of people with exceptional health-related traits.
Novo inks $50M metabolic disease pact with genomics biotech
2 days ago · Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populations.
Drug Company to Share Revenues With Indigenous People Who …
2 days ago · On Tuesday, his company, Variant Bio, based in Seattle, announced a $50 million collaboration with the drugmaker Novo Nordisk to develop drugs for metabolic disorders, including diabetes and ...
Seattle startup lands deal with Novo Nordisk to study obesity
2 days ago · Stephane Castel, Variant’s co-founder and chief technologist, hailed the deal with Novo Nordisk as an important next step in the evolution of the 40-person startup.
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two
1 day ago · Novo Nordisk expands Valo partnership, increasing eligible milestone payments to $4.6 billion for up to 20 drug programs. Variant Bio to receive $50 million upfront and R&D funding in Novo Nordisk ...
Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk …
2 days ago · Variant Bio announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease. The partnership between Novo Nordisk and Variant Bio is aimed at identifying and validating multiple novel targets with sufficient human genetic evidence to initiate human-centric drug discovery programs.
Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk …
2 days ago · Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease.
- Some results have been removed